Burkitt lymphoma is not an inherited disease. The genetic changes that drive this cancer are acquired during a person’s lifetime, not passed down from parent to child. The NIH’s Genetic and Rare Diseases Information Center states directly that while genetic changes involving the MYC gene are present in Burkitt lymphoma cells, these changes are acquired rather than inherited. That said, the relationship between genetics and this cancer is more nuanced than a simple yes or no, and understanding it can help clarify what “genetic” really means in the context of cancer.
Acquired Mutations, Not Inherited Ones
The confusion around Burkitt lymphoma and inheritance often comes from the fact that the disease does involve a genetic event: a chromosomal translocation. In nearly all cases, a section of chromosome 8 swaps places with a section of chromosome 14. This puts the MYC gene, which normally helps regulate cell growth, next to genes that are highly active in immune cells. The result is that MYC gets switched on permanently, driving uncontrolled cell division.
This translocation happens in individual B cells (a type of white blood cell) during a person’s life. It is a somatic mutation, meaning it occurs in one cell and affects only that cell’s descendants. It is not present in every cell of the body and cannot be passed to children through sperm or egg cells. When researchers sequenced the full genome of a Burkitt lymphoma tumor alongside the patient’s normal (germline) DNA, they found over 1,200 genetic variants that existed only in the tumor. These mutations were absent from the patient’s inherited genome.
So while Burkitt lymphoma is absolutely a “genetic” disease at the cellular level, it is not a “hereditary” one. The critical distinction: the DNA you’re born with does not contain the mutations that cause this cancer. They arise later, in a single cell that then multiplies out of control.
What Actually Triggers the Mutation
If the translocation isn’t inherited, the natural follow-up question is: what causes it to happen? The answer depends partly on which form of Burkitt lymphoma is involved. Three clinical variants exist: endemic, sporadic, and immunodeficiency-associated. They look identical under a microscope and behave similarly, but they arise under different circumstances.
The endemic form, most common in equatorial Africa, is strongly linked to two infections working together: Epstein-Barr virus (EBV) and malaria caused by the parasite Plasmodium falciparum. Repeated, intense malaria infections stress the immune system in several ways. Malaria-infected red blood cells directly bind to and activate B cells, pushing them to proliferate. At the same time, malaria suppresses the immune surveillance that normally keeps EBV-infected cells in check. EBV itself drives B cell growth, and when these cells are dividing rapidly with weakened immune oversight, the chance of a chromosomal accident like the MYC translocation rises significantly. Malaria can also trigger reactivation of dormant EBV and promote genomic instability in B cells. The combination of these forces creates conditions ripe for the translocation to occur.
The sporadic form, seen in North America and Europe, accounts for only 1 to 2 percent of adult lymphomas. EBV is found in a smaller proportion of these cases, and no single environmental trigger has been identified with the same clarity. The immunodeficiency-associated form occurs in people with HIV or other conditions that severely weaken immune function, again creating an environment where B cell growth goes unchecked.
Rare Familial Clusters
A small number of reports have documented Burkitt lymphoma occurring in more than one member of the same family, which understandably raises questions about inheritance. In one well-known study from a region of Tanzania where the disease is endemic, researchers identified five families with multiple cancer cases: two brothers and a half-brother all developed Burkitt lymphoma, another pair of brothers both developed it, and several families had Burkitt lymphoma alongside other rare cancers like nasopharyngeal carcinoma and chronic myelogenous leukemia. The clustering of two full sibling pairs with Burkitt lymphoma was statistically more than would be expected by chance.
The researchers suggested that genetic factors could influence susceptibility, but they could not rule out shared environmental exposure. Families living in the same area face the same malaria intensity, the same EBV exposure, and the same local environmental conditions. This makes it very difficult to separate a possible inherited vulnerability from a shared set of triggers. No specific gene has been identified that, when inherited, directly causes Burkitt lymphoma.
Inherited Immune Conditions That Raise Risk
While Burkitt lymphoma itself isn’t inherited, certain rare genetic syndromes can increase the overall risk of developing non-Hodgkin lymphomas, including Burkitt lymphoma. Children born with ataxia-telangiectasia or Wiskott-Aldrich syndrome have immune systems that don’t function properly from birth. This weakened immune surveillance means their bodies are less able to detect and destroy abnormal cells, raising the risk of lymphomas and other cancers.
These conditions are inherited in a straightforward way, following known patterns of genetic transmission from parent to child. But what’s inherited is the immune deficiency, not the lymphoma itself. The lymphoma, if it develops, still arises from acquired mutations in individual cells. Think of it as inheriting a vulnerability rather than inheriting the disease. Most people with Burkitt lymphoma do not have any of these underlying syndromes.
How the Diagnosis Works
Because the MYC translocation is acquired and found only in tumor cells, it serves as a diagnostic marker rather than something you’d screen for in healthy family members. Pathologists use a technique called fluorescent in situ hybridization (FISH) to look for the MYC rearrangement in tissue samples. This involves using fluorescent probes that bind to specific chromosome regions and light up under a microscope, revealing whether the translocation has occurred.
Two types of probes are commonly used, and laboratories ideally test with both, because using only one can sometimes miss the translocation. Newer sequencing technologies can also detect rearrangements that traditional FISH might not catch. These tests are performed on biopsy tissue from a suspected tumor. There is no blood test or genetic screening that predicts Burkitt lymphoma in advance, precisely because the causative mutations aren’t present in a person’s inherited DNA.
Survival and Treatment Outlook
Burkitt lymphoma is one of the fastest-growing human cancers, but it also responds well to treatment, particularly in children. Five-year survival for children is around 90 percent. For adults the rate drops to roughly 48 percent, and for elderly patients it falls further to about 29 percent. The median survival time for elderly patients is just 5 months, compared to 30 months for adults overall, reflecting both the aggressiveness of the disease and the challenges of tolerating intensive treatment at older ages.
The strong outcomes in children are largely due to the cancer’s high growth rate, which paradoxically makes it more sensitive to chemotherapy. Rapidly dividing cells are more vulnerable to drugs that target cell division. Because the disease is not inherited, siblings and children of someone diagnosed with Burkitt lymphoma do not need genetic testing or special screening protocols for this specific cancer.